NSABP B-59: Neoadjuvant Chemotherapy with Atezolizumab or Placebo for Triple Negative Breast Cancer (H-45197)
Description
Content
This study is being done to determine if the addition of atezolizumab to chemotherapy (weekly paclitaxel plus carboplatin followed by AC) improves response in the breast and lymph nodes (assessed pathologically at surgery) in patients with triple-negative breast cancer.
Contact
Phone 1: 713–798–1975
IRB: H-45197
Status:
Active
Created:
